AnaptysBio (NASDAQ:ANAB) Rating Reiterated by Leerink Partnrs

Leerink Partnrs reaffirmed their outperform rating on shares of AnaptysBio (NASDAQ:ANAB) in a research note published on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for AnaptysBio’s Q1 2024 earnings at ($1.41) EPS, Q2 2024 earnings at ($1.44) EPS, Q3 2024 earnings at ($1.45) EPS, Q4 2024 earnings at ($1.42) EPS, FY2024 earnings at ($5.71) EPS, Q1 2025 earnings at ($1.91) EPS, Q2 2025 earnings at ($1.86) EPS, Q3 2025 earnings at ($1.85) EPS, Q4 2025 earnings at ($1.14) EPS, FY2025 earnings at ($6.37) EPS, FY2026 earnings at ($4.82) EPS, FY2027 earnings at ($3.95) EPS and FY2028 earnings at ($3.39) EPS.

Several other research firms also recently issued reports on ANAB. SVB Leerink assumed coverage on shares of AnaptysBio in a research note on Tuesday. They set an outperform rating and a $47.00 price objective for the company. Stifel Nicolaus assumed coverage on shares of AnaptysBio in a research report on Wednesday, February 21st. They set a buy rating and a $50.00 target price on the stock. Wedbush raised shares of AnaptysBio from a neutral rating to an outperform rating and boosted their target price for the stock from $20.00 to $34.00 in a research report on Tuesday, March 12th. JPMorgan Chase & Co. reduced their target price on shares of AnaptysBio from $30.00 to $28.00 and set a neutral rating on the stock in a research report on Monday, April 1st. Finally, Wells Fargo & Company assumed coverage on shares of AnaptysBio in a research report on Thursday, April 11th. They set an overweight rating and a $56.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $46.22.

AnaptysBio Stock Up 0.6 %

ANAB opened at $21.47 on Tuesday. AnaptysBio has a 52-week low of $13.36 and a 52-week high of $27.50. The company has a 50 day moving average of $23.38 and a two-hundred day moving average of $20.55. The company has a market cap of $574.54 million, a P/E ratio of -3.53 and a beta of -0.30.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.74) by $0.15. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. The company had revenue of $9.01 million during the quarter, compared to the consensus estimate of $3.28 million. Research analysts anticipate that AnaptysBio will post -6.25 earnings per share for the current year.

Insider Transactions at AnaptysBio

In other news, CEO Daniel Faga sold 3,000 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the transaction, the chief executive officer now owns 749,087 shares in the company, valued at $16,045,443.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Dennis Mulroy sold 3,065 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $23.63, for a total transaction of $72,425.95. Following the completion of the transaction, the chief financial officer now owns 964 shares in the company, valued at approximately $22,779.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Daniel Faga sold 3,000 shares of the firm’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the transaction, the chief executive officer now owns 749,087 shares of the company’s stock, valued at approximately $16,045,443.54. The disclosure for this sale can be found here. Over the last quarter, insiders sold 157,005 shares of company stock worth $3,586,199. Insiders own 35.50% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Several large investors have recently made changes to their positions in the business. Fisher Asset Management LLC boosted its position in shares of AnaptysBio by 0.7% during the 4th quarter. Fisher Asset Management LLC now owns 71,154 shares of the biotechnology company’s stock valued at $1,524,000 after purchasing an additional 500 shares in the last quarter. Ensign Peak Advisors Inc boosted its position in shares of AnaptysBio by 1.1% during the 1st quarter. Ensign Peak Advisors Inc now owns 45,342 shares of the biotechnology company’s stock valued at $1,122,000 after purchasing an additional 510 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of AnaptysBio by 0.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 149,386 shares of the biotechnology company’s stock valued at $3,251,000 after purchasing an additional 555 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of AnaptysBio by 4.5% during the 2nd quarter. California State Teachers Retirement System now owns 23,523 shares of the biotechnology company’s stock valued at $478,000 after purchasing an additional 1,003 shares in the last quarter. Finally, UBS Group AG boosted its position in shares of AnaptysBio by 6.6% during the 4th quarter. UBS Group AG now owns 18,742 shares of the biotechnology company’s stock valued at $401,000 after purchasing an additional 1,156 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.